Oxford Asset Management’s Allena Pharmaceuticals ALNA Stock Holding History

Oxford Asset Management’s Portfolio ALNA Stock Details ALNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-21,572	Closed	-$151K	–	2035
2019 Q1	$151K	Sell	21,572 -10,536	-33%	-$76.4K	﹤0.01%	1541
2018 Q4	$175K	Buy	32,108 +15,515	+94%	+$134K	﹤0.01%	1570
2018 Q3	$178K	Buy	+16,593	New	+$182K	﹤0.01%	1613

Other funds holding ALNA

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

TGI

TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return

DVC

Deer VII & Co Larchmont, New York $317M AUM 30.89% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Oxford Asset Management's ALNA Position: Q2 2019 in Review

Oxford Asset Management sold out of Allena Pharmaceuticals (ALNA) in Q2 2019, closing a stake of 21,572 shares — an estimated $151K sold.

Oxford Asset Management first reported a position in ALNA in Q3 2018 and held it in 3 quarters. The position peaked at $178K in Q3 2018. 46 funds tracked by Wall St. Rank hold ALNA as of Q2 2019.

Oxford Asset Management reported no remaining Allena Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Oxford Asset Management sold 21,572 Allena Pharmaceuticals shares in Q2 2019, an estimated $151K.
Oxford Asset Management first reported a position in Allena Pharmaceuticals in Q3 2018 and held it in 3 quarters.
Oxford Asset Management's Allena Pharmaceuticals position peaked at $178K in Q3 2018.
46 funds tracked by Wall St. Rank held Allena Pharmaceuticals as of Q2 2019.

Based on Oxford Asset Management's 13F filing for Q2 2019, filed 14 Aug 2019.